Institutional & Family Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Institutional & Family Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$2.46K	Hold	398	–	–	﹤0.01%	560
2024 Q1	$2.02K	Hold	398	–	–	﹤0.01%	582
2023 Q4	$2.38K	Hold	398	–	–	﹤0.01%	548
2023 Q3	$2.82K	Hold	398	–	–	﹤0.01%	531
2023 Q2	$2.8K	Hold	398	–	–	﹤0.01%	544
2023 Q1	$3.32K	Hold	398	–	–	﹤0.01%	520
2022 Q4	$4.57K	Hold	398	–	–	﹤0.01%	482
2022 Q3	$5K	Sell	398 -2	-0.5%	-$26	﹤0.01%	469
2022 Q2	$4K	Hold	400	–	–	﹤0.01%	513
2022 Q1	$7K	Hold	400	–	–	﹤0.01%	481
2021 Q4	$6K	Hold	400	–	–	﹤0.01%	518
2021 Q3	$6K	Hold	400	–	–	﹤0.01%	624
2021 Q2	$6K	Hold	400	–	–	﹤0.01%	669
2021 Q1	$4K	Hold	400	–	–	﹤0.01%	708
2020 Q4	$3K	Hold	400	–	–	﹤0.01%	690
2020 Q3	$1K	Hold	400	–	–	﹤0.01%	767
2020 Q2	$2K	Hold	400	–	–	﹤0.01%	673
2020 Q1	$1K	Hold	400	–	–	﹤0.01%	706
2019 Q4	$1K	Hold	400	–	–	﹤0.01%	792
2019 Q3	$1K	Hold	400	–	–	﹤0.01%	766
2019 Q2	$2K	Hold	400	–	–	﹤0.01%	689
2019 Q1	$3K	Hold	400	–	–	﹤0.01%	649
2018 Q4	$3K	Hold	400	–	–	﹤0.01%	629
2018 Q3	$3K	Hold	400	–	–	﹤0.01%	664
2018 Q2	$2K	Hold	400	–	–	﹤0.01%	702
2018 Q1	$2K	Buy	+400	New	+$2.06K	﹤0.01%	699

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Institutional & Family Asset Management's BCRX Position: Q2 2024 in Review

Institutional & Family Asset Management held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2024 at 398 shares worth $2.46K. The position accounts for ﹤0.01% of the portfolio, ranked #560.

Institutional & Family Asset Management first reported a position in BCRX in Q1 2018 and has held it in 26 quarters since. The position peaked at $7K in Q1 2022. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

Institutional & Family Asset Management held 398 shares of BioCryst Pharmaceuticals worth $2.46K as of Q2 2024.
Institutional & Family Asset Management left its BioCryst Pharmaceuticals share count unchanged in Q2 2024.
BioCryst Pharmaceuticals made up ﹤0.01% of Institutional & Family Asset Management's portfolio in Q2 2024, its #560 holding.
Institutional & Family Asset Management first reported a position in BioCryst Pharmaceuticals in Q1 2018 and has held it in 26 quarters since.
Institutional & Family Asset Management's BioCryst Pharmaceuticals position peaked at $7K in Q1 2022.
241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on Institutional & Family Asset Management's 13F filing for Q2 2024, filed 5 Jul 2024.